Cyberonics To Present At The 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Dec 22, 8:00AM CST
Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015, in San Francisco.
JPM: 62.48 (unch), CYBX: 54.63 (+0.48)
Cyberonics Posts Positive Epilepsy Device Data, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:30PM CST
Cyberonics' (CYBX) AspireSR generator delivers programmed VNS therapy, along with the benefits of a new feature ??? Automatic Stimulation ??? which identifies seizures.
ETRM: 1.40 (-0.01), FLDM: 32.31 (+0.30), EW: 130.75 (+1.17), CYBX: 54.63 (+0.48)
Cyberonics Reports Consistently Positive Results From The E-36 And E-37 Studies For VNS Therapy Delivered By AspireSR® Generator
PR Newswire - Mon Dec 08, 10:45AM CST
Cyberonics, Inc. (NASDAQ:CYBX), maker of the VNS Therapy® System implanted in more than 80,000 patients, announced new results from two multi-site clinical studies of the AspireSR generator, E-36 (NCT01325623) and E-37 (NCT01846741), at the AES Annual Meeting in Seattle, Washington. The AspireSR generator is currently investigational in the U.S. and not approved for commercial use. The AspireSR generator attained the CE Mark and is now available in an increasing number of European countries.
CYBX: 54.63 (+0.48)
Cyberonics Earnings Review: 18 Days after Announcement Shares Down 2.0% (CYBX)
Comtex SmarTrend(R) - Mon Dec 08, 6:59AM CST
Two weeks ago on November 20th, 2014 Cyberonics (NASDAQ:CYBX) reported earnings and analysts, on average, expected earnings of $0.58 on sales of $75.6 million. The company actually reported EPS of $0.63 on sales of $73.4 million, beating EPS estimates by $0.05 and missing revenue estimates by $2.2 million. Shares of Cyberonics have slipped from $55.01 to $53.89, representing a loss of 2.0%, since the company reported earnings 18 days ago.
CYBX: 54.63 (+0.48)
MRI Interventions Welcomes Seasoned Medical Device Executive Wendelin Maners as Its New Vice President, Marketing
GlobeNewswire - Thu Dec 04, 7:33AM CST
MRI Interventions, Inc. (OTCQB:MRIC) today announces the addition of medical device veteran Wendelin Maners in the role of Vice President, Marketing, as CEO-elect Frank Grillo solidifies his management team. As Vice President, Marketing, Ms. Maners will head all marketing activities and programs, as well as develop and lead internal and external training programs for the Company.
BSX: 13.13 (+0.07), CYBX: 54.63 (+0.48)
Research and Markets: Global Neuroprosthetics Market 2013-2020: Medtronic, Boston Scientific, St. Jude Medical, Cyberonics, Retina Implant, MED-EL, Sonova & NDI Medical Dominate the $14 Billion Market
Business Wire - Wed Dec 03, 1:18PM CST
Research and Markets (http://www.researchandmarkets.com/research/sk8rcb/global) has announced the addition of the "Global Neuroprosthetics Market (Product Types, Technology, Application, and Geography) - Size, Share, Global Trends, Company Profiles, Analysis, Segmentation and Forecast, 2013 - 2020" report to their offering.
BSX: 13.13 (+0.07), MDT: 74.08 (+0.31), STJ: 66.67 (+0.67), CYBX: 54.63 (+0.48)
Global Neuroprosthetics Market 2013-2020: Medtronic, Boston Scientific, St. Jude Medical, Cyberonics, Retina Implant, MED-EL, Sonova & NDI Medical Dominate the $14 Billion Market
M2 - Wed Dec 03, 8:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/p6jtwz/global) has announced the addition of the "Global Neuroprosthetics Market (Product Types, Technology, Application, and Geography) - Size, Share, Global Trends, Company Profiles, Analysis, Segmentation and Forecast, 2013 - 2020" report to their offering. The global neuroprosthetics market is expected to reach $14 billion by 2020, registering a CAGR of 15.8% from 2014 to 2020 High growth segments such as Visual neuroprosthetics/retinal implants and applications such as Parkinson's disease, Overactive Bladder Syndrome and Epilepsy are expected to contribute substantially to the growth of the overall global Neuroprosthetics market. Motor Prosthetics holds the largest share within Neuroprosthetics devices market segment whereas Sacral Cord Stimulation (SCS) would maintain the leading market position through 2020, within technology segment. Multitude of cognitive and physiological disorders have a debilitating impact on 'quality-of-life' of affected patient populace. A majority (-80%) of such patients are unamenable to any form of treatment as first line (drug) and second line (invasive surgeries) treatments fail. Neuroprosthetics devices or neural implants or brain implants offer an efficacious solution to the afore-mentioned type of patients. Key findings of the study: - Global market for Neuroprosthetics gaining traction with Visual Prosthetics/ Retinal implants and Motor Neuroprosthetics (for treating Parkinson's disease) being major growth arenas during the forecast period (2014 - 2020) - Within Neuroprosthetics devices market, Visual Prosthetics/ Retinal implants is the fastest growing segment - Within Neuroprosthetics devices, Motor Neuroprosthetics segment would garner the largest market share, owing to numerous applications such as Parkinson's disease, Neurocardiac disorders, Over Active Bladder syndrome and Epilepsy - North America would be the lucrative market, both in terms of market size and growth, (among all regional markets) Some of the key market players profiled in this report are Medtronic, Boston Scientific Corporation, St. Jude Medical, Cyberonics Inc., Retina Implant AG, MED-EL, Sonova Group (Advanced Bionics AG) and NDI Medical LLC. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Neuroprosthetics Market By Technology, 2013-2020, $Million Chapter 5 Global Neuroprosthetics Market By Type, 2013-2020, $Million Chapter 6 Global Neuroprosthetics Market By Application, 2013-2020, $Million Chapter 7 Global Neuroprosthetics Market By Geography, 2013-2020, $Million Chapter 8 Company Profiles - Boston Scientific Corporation - Cochlear Limited - Cyberonics Inc. - Medtronic Inc. - NDI Medical LLC - Nervo Corp. - NeuroPace Inc. - Retina Implant AG - ST. Jude Medical - Sonova Group (Advanced Bionics AG) For more information visit http://www.researchandmarkets.com/research/p6jtwz/global
BSX: 13.13 (+0.07), MDT: 74.08 (+0.31), STJ: 66.67 (+0.67), CYBX: 54.63 (+0.48)
Today's Dead Cat Bounce Stock: Cyberonics (CYBX)
at The Street - Mon Nov 24, 9:39AM CST
Trade-Ideas LLC identified Cyberonics (CYBX) as a "dead cat bounce" (down big yesterday but up big today) candidate
CYBX: 54.63 (+0.48)
Cyberonics To Present At The 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Mon Nov 24, 8:00AM CST
Cyberonics, Inc. (NASDAQ: CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014, in New York.
CYBX: 54.63 (+0.48)
Cyberonics Slumps: CYBX Falls 5.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 7:50AM CST
Cyberonics has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past 24 hours
ETRM: 1.40 (-0.01), EW: 130.75 (+1.17), ANGO: 19.19 (+0.33), CYBX: 54.63 (+0.48)
Cyberonics Beats Q2 Earnings, Sales Up, EPS View Retained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 9:10AM CST
Cyberonics (CYBX) reported mixed second-quarter fiscal 2015 results, wherein the bottom line exceeded the Zacks Consensus Estimate, while the top line missed the same
ETRM: 1.40 (-0.01), EW: 130.75 (+1.17), ANGO: 19.19 (+0.33), CYBX: 54.63 (+0.48)
Cyberonics (CYBX) in Focus: Stock Adds 13.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 8:25AM CST
Cyberonics (CYBX) was a big mover last session, with shares rising over 13% on the day.
ETRM: 1.40 (-0.01), EW: 130.75 (+1.17), ANGO: 19.19 (+0.33), CYBX: 54.63 (+0.48)
Cyberonics profit beats again
at Investor's Business Daily - Thu Nov 20, 5:45PM CST
The Houston-based medical device maker reported a 26% rise in fiscal Q2 EPS to 63 cents per share, topping estimates by 5 cents a share. The company's earnings the prior quarter were below forecasts following 3 straight quarters of topping views....
CYBX: 54.63 (+0.48)
Nasdaq stocks posting largest percentage increases
AP - Thu Nov 20, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SPLS: 17.82 (-0.01), CLUB: 5.90 (-0.07), RESN: 8.79 (+0.45), CRMT: 51.59 (-0.12), BRDR: 8.52 (+0.05), KIRK: 23.38 (+0.14), MAGS: 5.48 (+0.29), DISH: 72.63 (+0.54), OPLK: 24.23 (-0.03), CYBX: 54.63 (+0.48)
Cyberonics' (CYBX) CEO Dan Moore on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 20, 5:00PM CST
CYBX: 54.63 (+0.48)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 11:46AM CST
NETE: 1.20 (unch), ANV: 0.88 (+0.02), LXRX: 0.90 (+0.02), CYAN: 7.00 (+0.50), JMEI: 15.09 (+0.21), LQDT: 8.19 (-0.19), KIRK: 23.38 (+0.14), IMNP: 1.89 (+0.02), RMTI: 8.41 (-0.07), FES: 1.19 (-0.01), DWCH: 9.08 (-0.07), AMDA: 0.64 (-0.01), CYBX: 54.63 (+0.48), BAMM: 1.70 (-0.04), CRMT: 51.59 (-0.12), EDAP: 1.97 (+0.01), BPTH: 2.80 (+0.03), MAGS: 5.48 (+0.29), RITT: 0.94 (-0.02), ENG: 1.80 (unch)
Cyberonics up after FQ2 report
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 9:21AM CST
CYBX: 54.63 (+0.48)
Cyberonics (CYBX) Marked As A Barbarian At The Gate
at The Street - Thu Nov 20, 9:17AM CST
Trade-Ideas LLC identified Cyberonics (CYBX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
CYBX: 54.63 (+0.48)
Cyberonics (CYBX) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 20, 7:55AM CST
CYBX: 54.63 (+0.48)